Enliven Therapeutics (ELVN) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$40.98
+0.9% on the day
+92.5% over 12 months
52-week range $15.14 – $61.15
Share price and insider trades
ELVN closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$77.1M
Insiders buying0
Insiders selling10
Enliven Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 10 sold $77.1M of ELVN stock on the open market.
Get emailed when insiders cluster-buy stocks like ELVN
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ELVN insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $607K | 1 |
| Q3 2026 | — | 0 | $11.8M | 23 |
| Q2 2026 | — | 0 | $52.9M | 21 |
| Q1 2026 | — | 0 | $10.1M | 21 |
| Q4 2025 | — | 0 | $1.6M | 11 |
| Q3 2025 | — | 0 | $66K | 1 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.2×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Enliven Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 10 insiders reported sales totaling $77.1M. 70 of 78 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 5SEC | J. Scott GarlandDirector | Sell | 13,000 | $46.67 | $607K | -12.2% | — |
| Sep 21SEC | Benjamin HohlCFO | Sell Plan | 3,53540,483 held (−8%) | $50.03 | $177K | -18.1% | — |
| Sep 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 2,91627,084 held (−10%) | $50.03 | $146K | -18.1% | — |
| Sep 21SEC | Benjamin HohlCFO | Sell Plan | 2,19438,289 held (−5%) | $50.72 | $111K | -19.2% | — |
| Sep 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 1,84425,240 held (−7%) | $50.71 | $94K | -19.2% | — |
| Sep 21SEC | Benjamin HohlCFO | Sell Plan | 28938,000 held (−1%) | $51.49 | $15K | -20.4% | — |
| Sep 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 24025,000 held (−1%) | $51.48 | $12K | -20.4% | — |
| Aug 19SEC | Benjamin HohlCFO | Sell Plan | 4,63041,424 held (−10%) | $58.35 | $270K | -29.8% | — |
| Aug 19SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 3,90026,100 held (−13%) | $58.37 | $228K | -29.8% | — |
| Aug 19SEC | Benjamin HohlCFO | Sell Plan | 1,38840,036 held (−3%) | $59.35 | $82K | -31.0% | — |
| Aug 19SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 1,10025,000 held (−4%) | $59.35 | $65K | -31.0% | — |
| Aug 6SEC | Mika K DerynckDirector | Sell Plan | 158,795 | $60.21 | $9.6M | -31.9% | — |
| Jul 21SEC | Benjamin HohlCFO | Sell Plan | 2,63846,177 held (−5%) | $53.38 | $141K | -23.2% | — |
| Jul 21SEC | Benjamin HohlCFO | Sell Plan | 2,56448,815 held (−5%) | $52.32 | $134K | -21.7% | — |
| Jul 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 2,18425,063 held (−8%) | $53.42 | $117K | -23.3% | — |
| Jul 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 2,06327,247 held (−7%) | $52.39 | $108K | -21.8% | — |
| Jul 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 45929,310 held (−2%) | $51.55 | $24K | -20.5% | — |
| Jul 21SEC | Benjamin HohlCFO | Sell Plan | 36951,379 held (−1%) | $51.48 | $19K | -20.4% | — |
| Jul 21SEC | Benjamin HohlCFO | Sell Plan | 32451,748 held (−1%) | $49.97 | $16K | -18.0% | — |
| Jul 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 23129,769 held (−1%) | $50.05 | $12K | -18.1% | — |
| Jul 21SEC | Benjamin HohlCFO | Sell Plan | 12346,054 held (−0%) | $53.87 | $7K | -23.9% | — |
| Jul 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 6325,000 held (−0%) | $53.92 | $3K | -24.0% | — |
| Jul 8SEC | Lori Anne KunkelDirector | Sell Plan | 5,88941,884 held (−12%) | $50.84 | $299K | -19.4% | — |
| Jul 8SEC | Lori Anne KunkelDirector | Sell Plan | 4,11147,773 held (−8%) | $49.98 | $205K | -18.0% | — |
| Jun 24SEC | Orbimed Advisors Llc10% Owner | Sell | 787,0246,601,878 held (−11%) | $45.38 | $35.7M | -9.7% | — |
| Jun 24SEC | Orbimed Advisors Llc10% Owner | Sell | 46,7766,555,102 held (−1%) | $45.00 | $2.1M | -8.9% | — |
| Jun 24SEC | Orbimed Advisors Llc10% Owner | Sell | 24,846220,882 held (−10%) | $45.38 | $1.1M | -9.7% | — |
| Jun 24SEC | Orbimed Advisors Llc10% Owner | Sell | 1,477219,405 held (−1%) | $45.00 | $66K | -8.9% | — |
| Jun 22SEC | Benjamin HohlCFO | Sell Plan | 3,40152,238 held (−6%) | $43.86 | $149K | -6.6% | — |
| Jun 22SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 2,59926,133 held (−9%) | $43.87 | $114K | -6.6% | — |
| Jun 22SEC | Benjamin HohlCFO | Sell Plan | 1,37955,639 held (−2%) | $42.79 | $59K | -4.2% | — |
| Jun 22SEC | Benjamin HohlCFO | Sell Plan | 1,23851,000 held (−2%) | $44.75 | $55K | -8.4% | — |
| Jun 22SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 1,26828,732 held (−4%) | $42.83 | $54K | -4.3% | — |
| Jun 22SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 1,13325,000 held (−4%) | $44.74 | $51K | -8.4% | — |
| Jun 17SEC | Orbimed Advisors Llc10% Owner | Sell | 272,3227,388,902 held (−4%) | $45.02 | $12.3M | -9.0% | — |
| Jun 17SEC | Orbimed Advisors Llc10% Owner | Sell | 9,086245,728 held (−4%) | $45.02 | $409K | -9.0% | — |
| Jun 9SEC | Lori Anne KunkelDirector | Sell Plan | 7,77954,105 held (−13%) | $34.28 | $267K | +19.5% | — |
| Jun 9SEC | Lori Anne KunkelDirector | Sell Plan | 1,86752,238 held (−3%) | $35.36 | $66K | +15.9% | — |
| Jun 9SEC | Lori Anne KunkelDirector | Sell Plan | 35451,884 held (−1%) | $35.82 | $13K | +14.4% | — |
| May 20SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 3,47526,525 held (−12%) | $39.53 | $137K | +3.7% | — |
| May 20SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 1,30225,223 held (−5%) | $40.25 | $52K | +1.8% | — |
| May 20SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 22325,000 held (−1%) | $41.21 | $9K | -0.6% | — |
| Apr 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 2,44125,000 held (−9%) | $48.06 | $117K | -14.7% | — |
| Apr 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 2,41927,441 held (−8%) | $47.39 | $115K | -13.5% | — |
| Apr 21SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 14029,860 held (−0%) | $45.81 | $6K | -10.5% | — |
| Mar 27SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 40,00025,000 held (−62%) | $35.10 | $1.4M | +16.8% | — |
| Mar 19SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 5,00025,000 held (−17%) | $27.76 | $139K | +47.6% | — |
| Mar 11SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 29,87125,000 held (−54%) | $30.02 | $897K | +36.5% | — |
| Mar 11SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 10,12925,000 held (−29%) | $30.19 | $306K | +35.7% | — |
| Mar 10SEC | Benjamin HohlCFO | Sell | 10,00051,000 held (−16%) | $29.58 | $296K | +38.5% | — |
| Feb 19SEC | Helen Louise CollinsChief Medical Officer | Sell Plan | 45,00025,000 held (−64%) | $26.17 | $1.2M | +56.6% | — |
| Feb 19SEC | Richard A. HeymanDirector | Sell Plan | 1,23022,647 held (−5%) | $26.18 | $32K | +56.5% | — |
| Feb 10SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 5,000740,188 held (−1%) | $29.04 | $145K | +41.1% | — |
| Jan 22SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 14,509745,188 held (−2%) | $26.90 | $390K | +52.3% | — |
| Jan 22SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 5,491759,697 held (−1%) | $26.37 | $145K | +55.4% | — |
| Jan 22SEC | Richard A. HeymanDirector | Sell Plan | 71823,877 held (−3%) | $26.96 | $19K | +52.0% | — |
| Jan 22SEC | Richard A. HeymanDirector | Sell Plan | 51224,595 held (−2%) | $26.46 | $14K | +54.9% | — |
| Jan 13SEC | Anish PatelCOO | Sell Plan | 48,057215,254 held (−18%) | $27.98 | $1.3M | +46.5% | — |
| Jan 13SEC | Anish PatelCOO | Sell Plan | 243215,011 held (−0%) | $28.50 | $7K | +43.8% | — |
| Jan 12SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 50,000765,188 held (−6%) | $29.13 | $1.5M | +40.7% | — |
| Jan 12SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 41,198815,188 held (−5%) | $24.90 | $1.0M | +64.6% | — |
| Jan 12SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 33,802856,386 held (−4%) | $24.92 | $842K | +64.4% | — |
| Jan 12SEC | Richard A. HeymanDirector | Sell Plan | 8,01529,392 held (−21%) | $25.04 | $201K | +63.7% | — |
| Jan 12SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 7,500890,188 held (−1%) | $20.13 | $151K | +103.6% | — |
| Jan 12SEC | Richard A. HeymanDirector | Sell Plan | 4,28525,107 held (−15%) | $25.00 | $107K | +63.9% | — |
| Jan 12SEC | Richard A. HeymanDirector | Sell Plan | 1,62025,545 held (−6%) | $25.00 | $40K | +63.9% | — |
| Dec 23SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 5,000897,688 held (−1%) | $16.84 | $84K | +143.3% | — |
| Dec 10SEC | Anish PatelCOO | Sell Plan | 4,958265,016 held (−2%) | $20.76 | $103K | +97.4% | — |
| Dec 10SEC | Anish PatelCOO | Sell Plan | 1,705263,311 held (−1%) | $21.78 | $37K | +88.2% | — |
| Nov 21SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 12,008903,180 held (−1%) | $22.30 | $268K | +83.8% | — |
| Nov 21SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 492902,688 held (−0%) | $23.09 | $11K | +77.5% | — |
| Nov 19SEC | Samuel KintzCEO, President | Sell Plan | 12,500890,392 held (−1%) | $21.82 | $273K | +87.8% | — |
| Nov 12SEC | Anish PatelCOO | Sell Plan | 6,054270,587 held (−2%) | $17.35 | $105K | +136.2% | — |
| Nov 12SEC | Anish PatelCOO | Sell Plan | 613269,974 held (−0%) | $17.94 | $11K | +128.4% | — |
| Oct 22SEC | Joseph P LyssikatosChief Scientific Officer | Sell Plan | 12,500915,188 held (−1%) | $22.08 | $276K | +85.6% | — |
| Oct 21SEC | Samuel KintzCEO, President | Sell Plan | 12,500902,892 held (−1%) | $21.33 | $267K | +92.1% | — |
| Oct 9SEC | Anish PatelCOO | Sell Plan | 6,667276,641 held (−2%) | $20.10 | $134K | +103.9% | — |
| Oct 1SEC | Benjamin HohlCFO | Sell Plan | 3,25023,000 held (−12%) | $20.40 | $66K | +100.9% | — |
Insiders at Enliven Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Orbimed Advisors Llc10% Owner | — | $51.7M | Jun 24, 2026 | — |
| Mika K DerynckDirector | — | $9.6M | Aug 6, 2026 | — |
| Helen Louise CollinsChief Medical Officer | — | $5.4M | Sep 21, 2026 | — |
| Joseph P LyssikatosChief Scientific Officer | — | $4.8M | Feb 10, 2026 | — |
| Anish PatelCOO | — | $1.7M | Jan 13, 2026 | — |
| Benjamin HohlCFO | — | $1.6M | Sep 21, 2026 | — |
| Lori Anne KunkelDirector | — | $850K | Jul 8, 2026 | — |
| J. Scott GarlandDirector | — | $607K | Oct 5, 2026 | — |
| Samuel KintzCEO, President | — | $539K | Nov 19, 2025 | — |
| Richard A. HeymanDirector | — | $413K | Feb 19, 2026 | — |
ELVN stock: common questions
Are Enliven Therapeutics, Inc. insiders buying ELVN stock?
In the past 12 months, 0 insiders reported open-market purchases of ELVN worth $0.
Are Enliven Therapeutics, Inc. insiders selling ELVN stock?
10 insiders reported sales worth $77.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ELVN's 52-week range?
Over the past year ELVN has traded between $15.14 and $61.15. It last closed at $40.98 on Oct 9, 2026.